Each ml contains Aminophylline BP 25 mg
Pharmacological classification & ATC Classification:
R03DA05 - aminophylline ; Belongs to the class of xanthines. Used
in the systemic treatment of obstructive airway s.
Aminophylline is a combination of theophylline and ethylenediamine.
Ethylenediamine is inactive; it increases the solubility of
theophylline in water. Theophylline relaxes bronchial smooth muscle.
Suggested mechanisms are an increase in intracellular cAMP through
inhibition of phosphodiesterase; receptor antagonism,
prostaglandin antagonism and effects on intracellular calcium.
Absorption: Rate of absorption delayed by food.
Distribution: Crosses the placenta and enters breast milk.
Metabolism: Undergoes hepatic metabolism.
Excretion: Via urine.
Aminophylline is a complex of theophylline and ethylenediamine and
is given for its theophylline activity to relax smooth muscle and to
relieve bronchial spasm.
Aminophylline Injection is indicated for relief of bronchospasm
associated with asthma and in chronic obstructive pulmonary .
Dosage & administration:
Acute severe bronchospasm
Adult: Loading dose: 5 mg/kg (ideal body weight) or 250-500 mg (25
mg/ml) by slow inj or infusion over 20-30 min. Maintenance infusion
dose: 0.5 mg/kg/hr. Max rate: 25 mg/min.
Child: Loading dose: same as adult dose. Maintenance dose: 6 mth-9
yr: 1 mg/kg/hr and 10-16 yr: 0.8 mg/kg/hr.
Elderly: Dose reduction may be ncessary.
Hepatic impairment: Dose reduction may be ncessary.
Special Populations: Reduce maintenance dose in patients with cor
pulmonale, heart failure or liver and in elderly. Increase
maintenance dose for smokers.
Incompatibility: Incompatible with metals.
Aminophylline injection should not be used in patients
hypersensitive to ethylenediamine or those allergic to the
theophyllines, caffeine or theobromine.
Aminophylline should not be administered concomitantly with other
xanthine drugs. When therapeutic doses of Aminophylline and/or
theophylline are administered simultaneously by more than one route
or in more than one preparation, the hazard of serious toxicity is
The use of Aminophylline IV in children under 6 months of age is
not generally recommended.
The use of Aminophylline is contra-indicated in patients with acute
Symptoms may include agitated maniacal behavior, frequent vomiting,
extreme thirst, slight fever, tinnitus, palpitation and arrhythmias.
Treatment is usually supportive and withdrawal of the drug.
Restoration of fluid and electrolyte balance is necessary.
Neonates, elderly, lactation, pregnancy, cardiac/hepatic s,
peptic ulceration, hyperthyroidism, hypertension, epilepsy, heart
failure, chronic alcoholism, acute febrile illness.
Nausea, vomiting, abdominal pain, diarrhoea, headache, insomnia,
dizziness, anxiety, restlessness; tremor, palpitations.
Potentially Fatal: Convulsions, cardiac arrhythmias, hypotension
and sudden death after too rapid IV injection.
Pregnancy & Lactation:
Category C: Either studies in animals have revealed adverse effects
on the foetus (teratogenic or embryocidal or other) and there are no
controlled studies in women or studies in women and animals are not
available. Drugs should be given only if the potential benefit
justifies the potential risk to the foetus.
Store below 25°C
(Also can be packed according to customers requirement)
10 ml Vials containing Aminophylline BP 25 mg/ml &
20 ml Vials containing Aminophylline BP 25 mg/ml